Otto Warburg observed in 1924 that tumor cells ferment glucose to lactate at a high rate even when oxygen is plentiful — "aerobic glycolysis." Normal, well-oxygenated cells send most pyruvate into the mitochondria for oxidative phosphorylation because it yields far more ATP per glucose:
Glycolysis (cytosol):
Glucose → 2 Pyruvate + 2 ATP (net, substrate-level)
Full oxidation (mitochondria, needs O₂):
Pyruvate + 3 O₂ → 3 CO₂ + ~14–15 ATP (TCA cycle + OXPHOS)
⇒ ≈ 30–32 ATP per glucose overall
Aerobic glycolysis (Warburg, O₂ not the bottleneck):
Pyruvate → Lactate (via LDH-A), bypasses mitochondria
⇒ only 2 ATP per glucose, but ~10-100× faster flux
The routing switch is a real enzyme gate: pyruvate dehydrogenase (PDH) normally feeds pyruvate into the TCA cycle. Oncogenic signaling (Myc, PI3K/Akt) and the hypoxia-inducible factor HIF-1α — stabilized in tumors even under normoxia — up-regulate PDK1, which phosphorylates and inhibits PDH, and simultaneously up-regulate GLUT1 (glucose uptake) and LDH-A (pyruvate→lactate). The result: glucose is diverted to fermentation regardless of oxygen supply.
- Cancer cell / Normal cell — presets a baseline glycolytic bias; cancer starts with PDK1 partially active even at normal pO₂.
- HIF-1α / oncogenic drive — raises PDK1 activity, gating more pyruvate away from the mitochondria into lactate production.
- Tissue O₂ (pO₂) — mitochondrial ATP synthesis needs O₂ as the terminal electron acceptor; a normal cell throttles glycolysis when O₂ is abundant (Pasteur effect), but a high-HIF₁ cancer cell keeps fermenting anyway.
- Glucose supply rate — sets how many glucose particles enter per second; readouts are per-glucose averages, so this mainly changes visual density and total counters.
Clinically this rewiring is the biochemical basis of FDG-PET tumor imaging (tumors take up a radiolabeled glucose analog voraciously) and a target for metabolic therapies (e.g. LDH-A or PDK inhibitors).